| Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells DT Saenz, W Fiskus, Y Qian, T Manshouri, K Rajapakshe, K Raina, ... Leukemia 31 (9), 1951-1961, 2017 | 171 | 2017 |
| BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells B Sun, W Fiskus, Y Qian, K Rajapakshe, K Raina, KG Coleman, AP Crew, ... Leukemia 32 (2), 343-352, 2018 | 161 | 2018 |
| EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling KJ Wilson, C Mill, S Lambert, J Buchman, TR Wilson, ... Growth Factors 30 (2), 107-116, 2012 | 134 | 2012 |
| RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1 CP Mill, W Fiskus, CD DiNardo, Y Qian, K Raina, K Rajapakshe, D Perera, ... Blood, The Journal of the American Society of Hematology 134 (1), 59-73, 2019 | 90 | 2019 |
| BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells DT Saenz, W Fiskus, T Manshouri, K Rajapakshe, S Krieger, B Sun, ... Leukemia 31 (3), 678-687, 2017 | 89 | 2017 |
| A high throughput, interactive imaging, bright‐field wound healing assay MD Zordan, CP Mill, DJ Riese, JF Leary Cytometry Part A 79 (3), 227-232, 2011 | 74 | 2011 |
| Dynamic Regulation of Long-Chain Fatty Acid Oxidation by a Noncanonical Interaction between the MCL-1 BH3 Helix and VLCAD S Escudero, E Zaganjor, S Lee, CP Mill, AM Morgan, EB Crawford, ... Molecular Cell 69 (5), 729-743. e7, 2018 | 65 | 2018 |
| Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells W Fiskus, T Cai, CD DiNardo, SM Kornblau, G Borthakur, TM Kadia, ... Blood cancer journal 9 (2), 4, 2019 | 61 | 2019 |
| SIRT2 deacetylates and inhibits the peroxidase activity of peroxiredoxin-1 to sensitize breast cancer cells to oxidant stress-inducing agents W Fiskus, V Coothankandaswamy, J Chen, H Ma, K Ha, DT Saenz, ... Cancer research 76 (18), 5467-5478, 2016 | 58 | 2016 |
| Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c) W Fiskus, S Boettcher, N Daver, CP Mill, K Sasaki, CE Birdwell, JA Davis, ... Blood cancer journal 12 (1), 5, 2022 | 52 | 2022 |
| ErbB2 is necessary for ErbB4 ligands to stimulate oncogenic activities in models of human breast cancer CP Mill, MD Zordan, SM Rothenberg, J Settleman, JF Leary, DJ Riese Genes & cancer 2 (8), 792-804, 2011 | 47 | 2011 |
| EGFR may couple moderate alcohol consumption to increased breast cancer risk CP Mill, JA Chester, DJ Riese Breast cancer: targets and therapy, 31-38, 2009 | 41 | 2009 |
| Biochemical and structural studies of N 5-carboxyaminoimidazole ribonucleotide mutase from the acidophilic bacterium Acetobacter aceti CZ Constantine, CM Starks, CP Mill, AE Ransome, SJ Karpowicz, ... Biochemistry 45 (27), 8193-8208, 2006 | 40 | 2006 |
| Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML DT Saenz, W Fiskus, T Manshouri, CP Mill, Y Qian, K Raina, ... Leukemia 33 (6), 1373-1386, 2019 | 39 | 2019 |
| Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2 CP Mill, W Fiskus, CD DiNardo, C Birdwell, JA Davis, TM Kadia, ... Blood, The Journal of the American Society of Hematology 139 (6), 907-921, 2022 | 38 | 2022 |
| Acidophilic adaptations in the structure of Acetobacter aceti N5-carboxyaminoimidazole ribonucleotide mutase (PurE) EC Settembre, JR Chittuluru, CP Mill, TJ Kappock, SE Ealick Acta Crystallographica Section D: Biological Crystallography 60 (10), 1753-1760, 2004 | 37 | 2004 |
| The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein LM Lucas, V Dwivedi, JI Senfeld, RL Cullum, CP Mill, JT Piazza, IN Bryant, ... Pharmacological Reviews 74 (1), 18-47, 2022 | 36 | 2022 |
| Autocrine-derived epidermal growth factor receptor ligands contribute to recruitment of tumor-associated macrophage and growth of basal breast cancer cells in vivo NK Nickerson, CP Mill, HJ Wu, DJ Riese, J Foley Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 20 …, 2012 | 34 | 2012 |
| Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors DT Saenz, W Fiskus, CP Mill, D Perera, T Manshouri, BH Lara, ... Blood, The Journal of the American Society of Hematology 135 (15), 1255-1269, 2020 | 33 | 2020 |
| Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines CP Mill, KL Gettinger, DJ Riese II Experimental cell research 317 (4), 392-404, 2011 | 33 | 2011 |
